NO324942B1 - Hydroksamderivater, farmasoytiske preparater inneholdende disse, anvendelse av derivatene samt fregangsmate for regulering av p21 promoter - Google Patents

Hydroksamderivater, farmasoytiske preparater inneholdende disse, anvendelse av derivatene samt fregangsmate for regulering av p21 promoter Download PDF

Info

Publication number: NO324942B1
Authority: NO; Norway
Prior art keywords: alkyl; aryl; cycloalkyl; heteroaryl; substituted
Prior art date: 2000-09-01

Application number

NO20030867A

Other languages

English (en)

Norwegian (no)

Other versions

NO20030867D0 (no

NO20030867L (no

Inventor

Richard William Versace

Stacy W Remiszewski

Kenneth Walter Bair

Michael A Green

Lawrence B Perez

Lidia Sambucetti

Sushil Kumar Sharma

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-01

Filing date

2003-02-25

Publication date

2008-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26923760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324942(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-25 Application filed by Novartis Ag filed Critical Novartis Ag

2003-02-25 Publication of NO20030867D0 publication Critical patent/NO20030867D0/no

2003-02-25 Publication of NO20030867L publication Critical patent/NO20030867L/no

2008-01-07 Publication of NO324942B1 publication Critical patent/NO324942B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
125000003118 aryl group Chemical group 0.000 claims description 283
150000001875 compounds Chemical class 0.000 claims description 117
125000000753 cycloalkyl group Chemical group 0.000 claims description 101
125000001072 heteroaryl group Chemical group 0.000 claims description 97
125000003710 aryl alkyl group Chemical group 0.000 claims description 82
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 78
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 70
125000000217 alkyl group Chemical group 0.000 claims description 60
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 59
229910052799 carbon Inorganic materials 0.000 claims description 53
125000002252 acyl group Chemical group 0.000 claims description 50
150000003839 salts Chemical class 0.000 claims description 50
125000001424 substituent group Chemical group 0.000 claims description 50
125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 46
150000002367 halogens Chemical class 0.000 claims description 46
-1 C 1 -C 4 alkyl Inorganic materials 0.000 claims description 45
229910052736 halogen Inorganic materials 0.000 claims description 45
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 38
229910052757 nitrogen Inorganic materials 0.000 claims description 37
229910052717 sulfur Inorganic materials 0.000 claims description 37
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
125000004122 cyclic group Chemical group 0.000 claims description 31
125000003282 alkyl amino group Chemical group 0.000 claims description 29
229910052760 oxygen Chemical group 0.000 claims description 27
125000002619 bicyclic group Chemical group 0.000 claims description 25
125000005842 heteroatom Chemical group 0.000 claims description 25
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
125000004103 aminoalkyl group Chemical group 0.000 claims description 24
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
125000005429 oxyalkyl group Chemical group 0.000 claims description 22
238000000034 method Methods 0.000 claims description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
125000004442 acylamino group Chemical group 0.000 claims description 16
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 10
125000004181 carboxyalkyl group Chemical group 0.000 claims description 10
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 10
125000001624 naphthyl group Chemical group 0.000 claims description 10
150000002825 nitriles Chemical class 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
230000002062 proliferating effect Effects 0.000 claims description 9
FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 7
ZLUZDKXBTNQWOL-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-(1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1CNCCC1=CNC2=CC=CC=C12 ZLUZDKXBTNQWOL-MDZDMXLPSA-N 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 5
101100135744 Caenorhabditis elegans pch-2 gene Proteins 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000001931 aliphatic group Chemical group 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
239000001301 oxygen Chemical group 0.000 claims description 5
239000011593 sulfur Chemical group 0.000 claims description 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
JGTCTTGDRUHLHS-MDZDMXLPSA-N (e)-3-[4-[[2-(1-benzofuran-3-yl)ethylamino]methyl]phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1CNCCC1=COC2=CC=CC=C12 JGTCTTGDRUHLHS-MDZDMXLPSA-N 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
101150020251 NR13 gene Proteins 0.000 claims description 3
125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 3
230000001105 regulatory effect Effects 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
210000004962 mammalian cell Anatomy 0.000 claims description 2
125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims 18
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
125000006177 alkyl benzyl group Chemical group 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
210000004027 cell Anatomy 0.000 description 45
206010028980 Neoplasm Diseases 0.000 description 29
239000000243 solution Substances 0.000 description 21
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
239000000203 mixture Substances 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
239000002253 acid Substances 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
238000011109 contamination Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
230000006907 apoptotic process Effects 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000010186 staining Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
108090000672 Annexin A5 Proteins 0.000 description 6
102000004121 Annexin A5 Human genes 0.000 description 6
239000002585 base Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000012981 Hank's balanced salt solution Substances 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000003638 chemical reducing agent Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 4
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000204031 Mycoplasma Species 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
KVXMLLMZXPRPNG-VOTSOKGWSA-N methyl (e)-3-(4-formylphenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(C=O)C=C1 KVXMLLMZXPRPNG-VOTSOKGWSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
150000003512 tertiary amines Chemical class 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
LBOUHDMYVURTMA-AATRIKPKSA-N (e)-3-(4-formylphenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(C=O)C=C1 LBOUHDMYVURTMA-AATRIKPKSA-N 0.000 description 3
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000006947 Histones Human genes 0.000 description 3
101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 3
101100232371 Hordeum vulgare IAT3 gene Proteins 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
102100034204 Transcription factor SOX-9 Human genes 0.000 description 3
229930189037 Trapoxin Natural products 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
150000003863 ammonium salts Chemical class 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
239000002609 medium Substances 0.000 description 3
JSFKISZGHQAGKO-ZHACJKMWSA-N methyl (e)-3-[4-[[2-(1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1CNCCC1=CNC2=CC=CC=C12 JSFKISZGHQAGKO-ZHACJKMWSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
108010060597 trapoxin A Proteins 0.000 description 3
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
DUCBSHDQTBWWLC-UHFFFAOYSA-N 2-[(2-chlorophenyl)methyl-(1,1,2,2,3,3,4,4,4-nonafluorobutylsulfonyl)amino]-n-hydroxypropanamide Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(C(C)C(=O)NO)CC1=CC=CC=C1Cl DUCBSHDQTBWWLC-UHFFFAOYSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
230000037057 G1 phase arrest Effects 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
239000003377 acid catalyst Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
230000006229 amino acid addition Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000025084 cell cycle arrest Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
KGSIGGLFUJYHRA-FOCLMDBBSA-N methyl (e)-3-[4-[[2-[tert-butyl(dimethyl)silyl]oxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1CN(CCO[Si](C)(C)C(C)(C)C)CCC1=CNC2=CC=CC=C12 KGSIGGLFUJYHRA-FOCLMDBBSA-N 0.000 description 2
KVXMLLMZXPRPNG-UHFFFAOYSA-N methyl 3-(4-formylphenyl)prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(C=O)C=C1 KVXMLLMZXPRPNG-UHFFFAOYSA-N 0.000 description 2
238000006772 olefination reaction Methods 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000008054 sulfonate salts Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RCIVUMDLBQZEHP-UHFFFAOYSA-N (2-methylpropan-2-yl)oxycarbamic acid Chemical compound CC(C)(C)ONC(O)=O RCIVUMDLBQZEHP-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
ANMUZPMNBWVZJL-UHFFFAOYSA-N 2-(2-methyl-1h-indol-3-yl)-2-oxoacetamide Chemical compound C1=CC=C2C(C(=O)C(N)=O)=C(C)NC2=C1 ANMUZPMNBWVZJL-UHFFFAOYSA-N 0.000 description 1
CPVSLHQIPGTMLH-UHFFFAOYSA-N 2-(2-methyl-1h-indol-3-yl)ethanamine Chemical compound C1=CC=C2C(CCN)=C(C)NC2=C1 CPVSLHQIPGTMLH-UHFFFAOYSA-N 0.000 description 1
XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 1
JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229940122964 Deacetylase inhibitor Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003893 Histone acetyltransferases Human genes 0.000 description 1
108090000246 Histone acetyltransferases Proteins 0.000 description 1
102000003964 Histone deacetylase Human genes 0.000 description 1
108090000353 Histone deacetylase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001067880 Homo sapiens Histone H4 Proteins 0.000 description 1
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012614 Q-Sepharose Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000006195 histone acetylation Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
RPLQUEPXYREGMA-VAWYXSNFSA-N methyl (e)-3-[4-[[2-(2-methyl-1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1CNCCC1=C(C)NC2=CC=CC=C12 RPLQUEPXYREGMA-VAWYXSNFSA-N 0.000 description 1
SLJZCNYOFBVRSA-CALJPSDSSA-N methyl (e)-3-[4-[[2-(2-methyl-1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enoate;hydrochloride Chemical compound Cl.C1=CC(/C=C/C(=O)OC)=CC=C1CNCCC1=C(C)NC2=CC=CC=C12 SLJZCNYOFBVRSA-CALJPSDSSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
LOYIGNDQOZNJNZ-UHFFFAOYSA-N n-hydroxy-2-[(4-methoxyphenyl)sulfonyl-[(4-nitrophenyl)methyl]amino]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(=O)NO)CC1=CC=C([N+]([O-])=O)C=C1 LOYIGNDQOZNJNZ-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
208000025440 neoplasm of neck Diseases 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
NZFHJBSDSXDUAO-UHFFFAOYSA-N o-tritylhydroxylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(ON)C1=CC=CC=C1 NZFHJBSDSXDUAO-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000013037 reversible inhibitor Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
229960002232 sodium phenylbutyrate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229930185603 trichostatin Natural products 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000037964 urogenital cancer Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Ceramic Engineering (AREA)
Manufacturing & Machinery (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Structural Engineering (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials Engineering (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Furan Compounds (AREA)
Pyrane Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20030867A 2000-09-01 2003-02-25 Hydroksamderivater, farmasoytiske preparater inneholdende disse, anvendelse av derivatene samt fregangsmate for regulering av p21 promoter NO324942B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22994300P	2000-09-01	2000-09-01
US29223201P	2001-05-18	2001-05-18
PCT/EP2001/010037 WO2002022577A2 (fr)	2000-09-01	2001-08-30	Inhibiteurs de desacetylase

Publications (3)

Publication Number	Publication Date
NO20030867D0 NO20030867D0 (no)	2003-02-25
NO20030867L NO20030867L (no)	2003-02-25
NO324942B1 true NO324942B1 (no)	2008-01-07

Family

ID=26923760

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20030867A NO324942B1 (no)	2000-09-01	2003-02-25	Hydroksamderivater, farmasoytiske preparater inneholdende disse, anvendelse av derivatene samt fregangsmate for regulering av p21 promoter
NO2015026C NO2015026I2 (no)	2000-09-01	2015-12-10	panobinostat eller et farmasøytisk akseptabelt salt derav

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2015026C NO2015026I2 (no)	2000-09-01	2015-12-10	panobinostat eller et farmasøytisk akseptabelt salt derav

Country Status (35)

Country	Link
US (5)	US6552065B2 (fr)
EP (2)	EP1318980B1 (fr)
JP (1)	JP4012819B2 (fr)
KR (1)	KR100585484B1 (fr)
CN (1)	CN1300110C (fr)
AR (1)	AR035057A1 (fr)
AT (1)	ATE376999T1 (fr)
AU (2)	AU2001282129B2 (fr)
BE (1)	BE2015C062I2 (fr)
BR (1)	BRPI0113669B8 (fr)
CA (1)	CA2420899C (fr)
CY (2)	CY1107839T1 (fr)
CZ (1)	CZ302707B6 (fr)
DE (1)	DE60131179T2 (fr)
DK (1)	DK1318980T3 (fr)
EC (1)	ECSP034492A (fr)
ES (1)	ES2292610T3 (fr)
FR (1)	FR15C0086I2 (fr)
HU (2)	HU229796B1 (fr)
IL (2)	IL154574A0 (fr)
LU (1)	LU92890I2 (fr)
MX (1)	MXPA03001832A (fr)
MY (1)	MY136892A (fr)
NL (1)	NL300778I2 (fr)
NO (2)	NO324942B1 (fr)
NZ (1)	NZ524365A (fr)
PE (1)	PE20020354A1 (fr)
PL (1)	PL221738B1 (fr)
PT (1)	PT1318980E (fr)
RU (1)	RU2302408C3 (fr)
SI (1)	SI1318980T1 (fr)
SK (1)	SK287609B6 (fr)
TW (1)	TWI286544B (fr)
WO (1)	WO2002022577A2 (fr)
ZA (1)	ZA200301423B (fr)

Families Citing this family (471)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6777217B1 (en)	1996-03-26	2004-08-17	President And Fellows Of Harvard College	Histone deacetylases, and uses related thereto
US6822267B1 (en) *	1997-08-20	2004-11-23	Advantest Corporation	Signal transmission circuit, CMOS semiconductor device, and circuit board
CA2391952C (fr)	1999-11-23	2012-01-31	Methylgene Inc.	Inhibiteurs de l'histone deacetylase
US20030129724A1 (en)	2000-03-03	2003-07-10	Grozinger Christina M.	Class II human histone deacetylases, and uses related thereto
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002026696A1 (fr)	2000-09-29	2002-04-04	Prolifix Limited	Composes d'acide carbamique comprenant un enchainement amide comme inhibiteurs hdac
US7312247B2 (en) *	2001-03-27	2007-12-25	Errant Gene Therapeutics, Llc	Histone deacetylase inhibitors
WO2003032921A2 (fr)	2001-10-16	2003-04-24	Sloan-Kettering Institute For Cancer Research	Traitement des maladies neurodegeneratives et du cancer du cerveau
NZ544689A (en) *	2001-11-06	2007-08-31	Novartis Ag	Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
NZ550185A (en)	2002-03-04	2008-10-31	Merck Hdac Res Llc	Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US7148257B2 (en)	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
BR0308908A (pt)	2002-04-03	2005-01-04	Topotarget Uk Ltd	Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
AU2003219595A1 (en) *	2002-04-11	2003-10-27	In2Gen Co., Ltd.	Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
WO2003088954A1 (fr) *	2002-04-15	2003-10-30	Sloan-Kettering Institute For Cancer Research	Polytherapie pour le traitement de cancer
BR0311714A (pt) *	2002-06-10	2005-03-01	Novartis Ag	Combinações que compreendem epotilonas e seus usos farmacêuticos
CA2495354A1 (fr) *	2002-08-20	2004-03-04	Yamanouchi Pharmaceutical Co., Ltd.	Agent inhibant la degradation de la matrice extracellulaire du cartilage articulaire
CA2498210C (fr) *	2002-09-13	2011-10-18	Virginia Commonwealth University	Combinaison de a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine et b) d'un inhibiteur de l'histone deacetylase pour le traitement de la leucemie
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7250514B1 (en)	2002-10-21	2007-07-31	Takeda San Diego, Inc.	Histone deacetylase inhibitors
AU2003280838A1 (en) *	2002-11-19	2004-06-15	Takeda Pharmaceutical Company Limited	Indole derivatives as somatostatin agonists or antagonists
AU2003296310A1 (en)	2002-12-06	2004-06-30	University Of South Florida	Histone deacetylase inhibitor enhancement of trail-induced apoptosis
TW200418806A (en) *	2003-01-13	2004-10-01	Fujisawa Pharmaceutical Co	HDAC inhibitor
AU2004205372B2 (en)	2003-01-17	2011-02-24	Topotarget Uk Limited	Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
AU2003900608A0 (en) *	2003-02-11	2003-02-27	Fujisawa Pharmaceutical Co., Ltd.	Hdac inhibitor
AU2003900587A0 (en) *	2003-02-11	2003-02-27	Fujisawa Pharmaceutical Co., Ltd.	Hdac inhibitor
WO2004076386A2 (fr)	2003-02-25	2004-09-10	Topotarget Uk Limited	Composes d'acide carbamique comprenant un groupe heteroaryle bicyclique utilises en tant qu'inhibiteurs de hdac
KR20050122210A (ko)	2003-03-17	2005-12-28	다케다 샌디에고, 인코포레이티드	히스톤 탈아세틸화 효소 억제제
MXPA05012464A (es) *	2003-05-21	2006-01-30	Novartis Ag	Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
WO2005011598A2 (fr) *	2003-07-31	2005-02-10	University Of South Florida	Composition et methode de traitement de la leucemie
US20060270730A1 (en) *	2003-08-07	2006-11-30	Andreas Katopodis	Histone deacetylase inhibitors as immunosuppressants
JP2007501774A (ja) *	2003-08-08	2007-02-01	ノバルティスアクチエンゲゼルシャフト	スタウロスポリンを含む組み合わせ
EP1663194B1 (fr)	2003-08-26	2010-03-31	Merck HDAC Research, LLC	Utilisation de SAHA pour traiter le mésotheliome
JP2007504131A (ja)	2003-08-29	2007-03-01	エートンファーマインコーポレーティッド	癌の組み合わせ処置法
CN100455564C (zh) *	2003-09-12	2009-01-28	深圳微芯生物科技有限责任公司	组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
AU2004271730A1 (en) *	2003-09-18	2005-03-24	Novartis Ag	Combination of a histone deacetylase inhibitor with a death receptor ligand
KR101127201B1 (ko)	2003-09-22	2012-04-12	에스*바이오 피티이 리미티드	벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
PL1673349T3 (pl) *	2003-09-22	2010-11-30	Mei Pharma Inc	Pochodne benzimidazolu: wytwarzanie i zastosowania farmaceutyczne
US20080085902A1 (en) *	2003-09-23	2008-04-10	Guido Bold	Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
US20070167499A1 (en) *	2003-10-27	2007-07-19	A*Bio Pte Ltd.	Biaryl linked hydroxamates: preparation and pharmaceutical applications
US9115090B2 (en)	2003-12-02	2015-08-25	The Ohio State University Research Foundation	Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
EP1541549A1 (fr) *	2003-12-12	2005-06-15	Exonhit Therapeutics S.A.	Dérivés tricycliques d'hydroxamate et de benzamide, compositions et methodes
WO2005065681A1 (fr) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	Derives de n-hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide et composes associes en tant qu'inhibiteurs d'histone deacetylase pour le traitement du cancer
WO2005066151A2 (fr) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	Inhibiteurs d'histone desacetylase
US20050197336A1 (en) *	2004-03-08	2005-09-08	Miikana Therapeutics Corporation	Inhibitors of histone deacetylase
US7345043B2 (en) *	2004-04-01	2008-03-18	Miikana Therapeutics	Inhibitors of histone deacetylase
RS52545B (sr)	2004-04-07	2013-04-30	Novartis Ag	Inhibitori protein apoptoze (iap)
EP1771167A4 (fr) *	2004-07-19	2010-04-21	Merck Sharp & Dohme	Inhibiteurs de l'histone deacetylase
JP4946861B2 (ja) *	2004-08-09	2012-06-06	アステラス製薬株式会社	ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
ITMI20041869A1 (it) *	2004-10-01	2005-01-01	Dac Srl	Nuovi inibitori delle istone deacetilasi
US8242175B2 (en)	2004-10-01	2012-08-14	Dac S.R.L.	Class of histone deacetylase inhibitors
US20070021612A1 (en) *	2004-11-04	2007-01-25	University Of Notre Dame Du Lac	Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en)	2004-11-04	2007-06-26	University Of Notre Dame Du Lac	Process for preparing histone deacetylase inhibitors and intermediates thereof
JP2008524246A (ja)	2004-12-16	2008-07-10	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
CA2596015A1 (fr)	2005-02-14	2006-08-24	Sampath K. Anandan	Composes heterocycliques fusionnes utiles comme inhibiteurs de l'histone deacetylase
US7666880B2 (en) *	2005-03-21	2010-02-23	S*Bio Pte Ltd.	Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
US8999289B2 (en)	2005-03-22	2015-04-07	President And Fellows Of Harvard College	Treatment of protein degradation disorders
GB0509223D0 (en) *	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Enzyme inhibitors
GB0509225D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Inhibitors of enzymatic activity
WO2006122319A2 (fr)	2005-05-11	2006-11-16	Takeda San Diego, Inc.	Inhibiteurs d'histone deacetylase
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
TWI415603B (zh)	2005-05-20	2013-11-21	Merck Sharp & Dohme	１，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅｈｙｄｒｏｘａｍｉｃａｃｉｄ）之調配物及其製配方法
ZA200800901B (en)	2005-07-14	2010-05-26	Takeda San Diego Inc	Histone deacetylase inhibitors
WO2007016532A2 (fr) *	2005-08-02	2007-02-08	Novartis Ag	Mutations et polymorphismes de hdac4
PL1912640T3 (pl)	2005-08-03	2015-11-30	Novartis Ag	Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka
MX2008001964A (es) *	2005-08-10	2008-03-26	Novartis Ag	Metodo de uso de inhibidores de desacetilasa.
JP2009504674A (ja) *	2005-08-11	2009-02-05	ノバルティスアクチエンゲゼルシャフト	有機化合物の組合せ
EP1940805A4 (fr) *	2005-08-26	2009-11-11	Methylgene Inc	Inhibiteurs d'analogues de benzodiazepine et de benzopiperazine de l'histone deacetylase
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
WO2007030455A2 (fr) *	2005-09-07	2007-03-15	Novartis Ag	Mutations et polymorphismes de hdac10
WO2007030454A2 (fr) *	2005-09-07	2007-03-15	Novartis Ag	Mutations et polymorphismes de hdac9
WO2007038073A2 (fr) *	2005-09-22	2007-04-05	Novartis Ag	Mutations et polymorphismes de l’hdac11
CA2623034A1 (fr)	2005-09-27	2007-04-05	Novartis Ag	Composes de carboxyamine et leurs methodes d'utilisation
WO2007047998A2 (fr) *	2005-10-21	2007-04-26	Novartis Ag	Mutations et polymorphismes du gène de l'hdac2
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
BRPI0617806A2 (pt) *	2005-10-24	2011-08-09	Novartis Ag	combinação de inibidores de histona desacetilase com radiação
WO2007053596A1 (fr)	2005-10-31	2007-05-10	Braincells, Inc.	Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
WO2007053502A2 (fr) *	2005-11-01	2007-05-10	Novartis Ag	Mutations et polymorphismes de l'hdac5
WO2007058992A2 (fr) *	2005-11-14	2007-05-24	Novartis Ag	Mutations et polymorphismes de hdac6
EP2275103B1 (fr)	2005-11-21	2014-04-23	Novartis AG	Inhibiteurs du mTOR pour le traitement des tumeurs endocriniennes
US20070207950A1 (en) *	2005-12-21	2007-09-06	Duke University	Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (fr) *	2006-01-13	2007-07-26	Takeda San Diego, Inc.	Inhibiteurs des histone desacetylases
RU2008135979A (ru)	2006-02-07	2010-03-20	Астеллас Фарма Инк. (Jp)	Соединения гидроксиакрилаимда
US8222423B2 (en) *	2006-02-14	2012-07-17	Dana-Farber Cancer Institute, Inc.	Bifunctional histone deacetylase inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
JP2009532503A (ja)	2006-04-05	2009-09-10	ノバルティスアクチエンゲゼルシャフト	癌を処置するための治療剤の組合せ
CN102861338A (zh)	2006-04-05	2013-01-09	诺瓦提斯公司	用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
US8168383B2 (en)	2006-04-14	2012-05-01	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
EP2447359B1 (fr)	2006-04-14	2015-11-04	Cell Signaling Technology, Inc.	Défauts de gène et ALK kinase mutante dans des tumeurs solides humaines
CA2649877A1 (fr)	2006-04-24	2007-12-21	Gloucester Pharmaceuticals	Therapie de combinaison de gemcitabine
US20090018142A9 (en) *	2006-05-02	2009-01-15	Zhengping Zhuang	Use of phosphatases to treat tumors overexpressing N-CoR
WO2007134136A2 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenèse par modulation de l'angiotensine
US20090317489A1 (en)	2006-05-09	2009-12-24	Hanspeter Nick	Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
WO2007134077A2 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenèse induite par le récepteur 5ht
WO2007146730A2 (fr)	2006-06-08	2007-12-21	Gloucester Pharmaceuticals	Thérapie à base d'inhibiteurs de désacétylase (dac)
KR20090015968A (ko)	2006-06-12	2009-02-12	노파르티스 아게	Ｎ-히드록시-3-[4-[[[2-(2-메틸-1ｈ-인돌-3-일)에틸]아미노]메틸]페닐]-2ｅ-2-프로펜아미드의 동질이상체
HRP20130798T1 (en) *	2006-06-12	2013-09-30	Novartis Ag	Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
CN101466672B (zh) *	2006-06-12	2012-05-16	诺瓦提斯公司	N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
MX2008015901A (es) *	2006-06-12	2009-01-12	Novartis Ag	Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]met il]fenil]-2e-2-propenamida.
RU2008151724A (ru) *	2006-06-12	2010-07-20	Новартис АГ (CH)	Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
BRPI0713013A2 (pt) *	2006-06-26	2012-04-03	Novartis Ag	compostos orgánicos
EP2068872A1 (fr)	2006-09-08	2009-06-17	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2561835T3 (es)	2006-09-20	2016-03-01	Mei Pharma, Inc.	Compuestos hidroxamato de imidazo[1,2-a]piridina que son inhibidores de la histona desacetilasa
CA2663614A1 (fr) *	2006-09-28	2008-04-10	Merck And Co., Inc.	Sels a base d'acide suberoylanilide-hydroxamique (saha) et des formes polymorphes de ceux-ci
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
GB0619753D0 (en)	2006-10-06	2006-11-15	Chroma Therapeutics Ltd	Enzyme inhibitors
JP5043120B2 (ja)	2006-10-30	2012-10-10	クロマセラピューティクスリミテッド	ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
US20080242648A1 (en) *	2006-11-10	2008-10-02	Syndax Pharmaceuticals, Inc., A California Corporation	COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008070011A2 (fr) *	2006-12-04	2008-06-12	Novartis Ag	Combinaison
US20100069388A1 (en) *	2006-12-15	2010-03-18	Astellas Pharma Inc.	N-hydroxyacrylamide compounds
KR20090098920A (ko) *	2007-01-10	2009-09-17	노파르티스 아게	데아세틸라제 억제제의 제제
BRPI0806365B8 (pt)	2007-02-06	2021-05-25	Lixte Biotechnology Holdings Inc	composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
EP2491923A3 (fr)	2007-02-15	2012-12-26	Novartis AG	Combinaisons d'agents thérapeutiques pour traiter le cancer
KR20090125209A (ko)	2007-03-28	2009-12-03	산텐 세이야꾸 가부시키가이샤	히스톤 탈아세틸화 효소 저해 작용을 갖는 화합물을 유효 성분으로서 함유하는 안압 하강제
JP5746860B2 (ja) *	2007-04-09	2015-07-08	メチルジーンインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
AU2008247603A1 (en) *	2007-05-04	2008-11-13	Novartis Ag	Use of HDAC inhibitors for the treatment of gastrointestinal cancers
MX2009012179A (es) *	2007-05-11	2009-12-01	Novartis Ag	Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de melanoma.
CA2687274A1 (fr) *	2007-05-30	2008-12-11	Novartis Ag	Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse
US7737175B2 (en)	2007-06-01	2010-06-15	Duke University	Methods and compositions for regulating HDAC4 activity
WO2009020565A1 (fr) *	2007-08-03	2009-02-12	Lixte Biotechnology, Inc.	Utilisation de phosphates pour traiter des neuroblastomes et des médulloblastomes
CL2008002786A1 (es) *	2007-09-20	2009-05-15	Novartis Ag	Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
WO2009045440A1 (fr)	2007-10-01	2009-04-09	Lixte Biotechnology Holdings, Inc.	Inhibiteurs de hdac
KR20100074288A (ko) *	2007-10-22	2010-07-01	오키드 리서치 레버라토리즈 리미티드	히스톤 디아세틸라제 억제제
CN101417967A (zh) *	2007-10-26	2009-04-29	浙江海正药业股份有限公司	组蛋白去乙酰酶抑制剂、其组合物及其应用
WO2009067453A1 (fr) *	2007-11-19	2009-05-28	Syndax Pharmaceuticals, Inc.	Combinaisons d'inhibiteurs de la hdac et d'inhibiteurs de protéasomes
WO2009067808A1 (fr) *	2007-11-27	2009-06-04	Ottawa Health Research Institute	Amplification d'une infection par un virus oncolytique spécifique au cancer par des inhibiteurs d'histone désacétylase
CA2708281A1 (fr)	2007-12-11	2009-08-27	Viamet Pharmaceuticals, Inc.	Inhibiteurs de metalloenzymes utilisant des fractions de liaison a un metal en combinaison avec des fractions de ciblage
ITFI20070288A1 (it)	2007-12-21	2009-06-22	A I L Firenze Sezione Autonoma	Inibitori delle deacetilasi istoniche
EP2100879A1 (fr) *	2008-03-13	2009-09-16	4Sc Ag	Nouveaux composants d'acide hydroxamique tetrahydroisoquinoline/ isoindoline substitués N
AU2009228765B2 (en)	2008-03-24	2012-05-31	Novartis Ag	Arylsulfonamide-based matrix metalloprotease inhibitors
PT2260020E (pt)	2008-03-26	2014-10-28	Novartis Ag	Inibidores das desacetilases b baseados no hidroxamato
EP2306996A1 (fr) *	2008-07-18	2011-04-13	Novartis AG	Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin
US8440716B2 (en)	2008-07-23	2013-05-14	President And Fellows Of Harvard College	Deacetylase inhibitors and uses thereof
US8058268B2 (en) *	2008-08-01	2011-11-15	Lixte Biotechnology, Inc.	Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CA2730428A1 (fr) *	2008-08-01	2010-02-04	Lixte Biotechnology, Inc.	Procedes de regulation de la mitose cellulaire par inhibition de la phosphatase de serine/threonine
WO2010147612A1 (fr)	2009-06-18	2010-12-23	Lixte Biotechnology, Inc.	Procédés de modulation de la régulation cellulaire par inhibition de p53
US8227473B2 (en)	2008-08-01	2012-07-24	Lixte Biotechnology, Inc.	Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010083617A1 (fr)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
GB0903480D0 (en) *	2009-02-27	2009-04-08	Chroma Therapeutics Ltd	Enzyme Inhibitors
KR101168801B1 (ko)	2009-03-27	2012-07-25	주식회사종근당	신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
US7994357B2 (en)	2009-04-03	2011-08-09	Naturewise Biotech & Medicals Corporation	Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
ES2473792T3 (es)	2009-04-03	2014-07-07	Naturewise Biotech & Medicals Corporation	Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
EP2454267A2 (fr)	2009-07-16	2012-05-23	Royal College of Surgeons in Ireland	Complexes métalliques ayant une double activité inhibitrice d'histone désacétylase et de liaison à l'adn
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8716344B2 (en)	2009-08-11	2014-05-06	President And Fellows Of Harvard College	Class- and isoform-specific HDAC inhibitors and uses thereof
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en)	2009-08-17	2017-06-30	Intellikine Llc	Heterocyclic compounds and uses thereof
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
AU2010288534A1 (en)	2009-08-26	2012-03-15	Novartis Ag	Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
US20110053925A1 (en) *	2009-08-28	2011-03-03	Novartis Ag	Hydroxamate-Based Inhibitors of Deacetylases
AR077975A1 (es)	2009-08-28	2011-10-05	Irm Llc	Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
MY156209A (en)	2009-11-04	2016-01-29	Novartis Ag	Heterocyclic sulfonamide derivatives useful mek inhibitors
EP2503888A4 (fr)	2009-11-23	2015-07-29	Cerulean Pharma Inc	Polymères à base de cyclodextrine pour une administration thérapeutique
JP5456908B2 (ja)	2009-12-08	2014-04-02	ノバルティスアーゲー	ヘテロ環式スルホンアミド誘導体
AU2012265844A1 (en)	2009-12-08	2013-05-02	Novartis Ag	Heterocyclic sulfonamide derivatives
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
US20130040998A1 (en) *	2010-01-08	2013-02-14	Dana-Farber Cancer Institute, Inc.	Fluorinated hdac inhibitors and uses thereof
WO2011088192A1 (fr)	2010-01-13	2011-07-21	Tempero Pharmaceuticals, Inc.	Composés et procédés
KR101781663B1 (ko)	2010-01-13	2017-09-25	템페로 파마슈티칼즈, 인크.	히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
US20110178287A1 (en)	2010-01-19	2011-07-21	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
UY33236A (es)	2010-02-25	2011-09-30	Novartis Ag	Inhibidores dimericos de las iap
WO2011119995A2 (fr)	2010-03-26	2011-09-29	Cerulean Pharma Inc.	Formulations et procédés d'utilisation
US8217079B2 (en)	2010-03-26	2012-07-10	Italfarmaco Spa	Method for treating Philadelphia-negative myeloproliferative syndromes
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
EP2407164A1 (fr)	2010-07-14	2012-01-18	Dublin Institute of Technology Intellectual Property Ltd	Complexes de cuivre II et de phenanthroline et leur utilisation dans le traitement du cancer
WO2012025701A1 (fr) *	2010-08-25	2012-03-01	Chroma Therapeutics Ltd.	Dérivés d'ester de glycine alpha, alpha-disubstituée et leur utilisation comme inhibiteurs des hdac
WO2012025155A1 (fr) *	2010-08-26	2012-03-01	Novartis Ag	Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases
CN103189353A (zh) *	2010-08-27	2013-07-03	诺瓦提斯公司	基于异羟肟酸的脱乙酰酶抑制剂
CN103261186A (zh)	2010-12-13	2013-08-21	诺瓦提斯公司	二聚化iap抑制剂
UY33794A (es)	2010-12-13	2012-07-31	Novartis Ag	Inhibidores diméricos de las iap
EP2663312B1 (fr)	2011-01-10	2017-10-11	Nimbus Iris, Inc.	Inhibiteurs d'irak et leurs utilisation
TW201245115A (en)	2011-01-24	2012-11-16	Chdi Foundation Inc	Histone deacetylase inhibitors and compositions and methods of use thereof
JP2014505088A (ja)	2011-02-10	2014-02-27	ノバルティスアーゲー	Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (fr)	2011-02-23	2016-08-10	Intellikine, LLC	Composés hétérocycliques et leurs utilisations
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
ES2842970T3 (es)	2011-03-09	2021-07-15	Cereno Scient Ab	Compuestos y métodos para mejorar la fibrinólisis endógena alterada usando inhibidores de la histona desacetilasa
CA2844407A1 (fr)	2011-06-14	2012-12-20	Novartis Ag	Combinaison de panobinostat et de ruxolitinib dans le traitement du cancer tel qu'un neoplasme myeloproliferatif
US8859535B2 (en)	2011-06-20	2014-10-14	Novartis Ag	Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (fr)	2011-06-20	2015-04-29	Novartis AG	Composés de cyclohexyl-isoquinolinone
CA2840315A1 (fr)	2011-06-27	2013-01-03	Novartis Ag	Formes solides et sels de derives de tetrahydro-pyrido-pyrimidine
EP2758043A4 (fr)	2011-08-17	2016-02-24	Dennis M Brown	Compositions et procédés pour améliorer le bénéfice thérapeutique de composés chimiques administrés de manière suboptimale, notamment des hexitols substitués tels que le dibromodulcitol
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
US11007194B2 (en)	2011-11-11	2021-05-18	Array Biopharma Inc.	Method of treating a proliferative disease
WO2013078264A1 (fr)	2011-11-23	2013-05-30	Novartis Ag	Formulations pharmaceutiques
CN103130673B (zh) *	2011-11-28	2017-05-03	重庆医药工业研究院有限责任公司	一种阿戈美拉晶型i的制备方法
US8969341B2 (en)	2011-11-29	2015-03-03	Novartis Ag	Pyrazolopyrrolidine compounds
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
WO2013093850A1 (fr)	2011-12-22	2013-06-27	Novartis Ag	Dérivés quinoline
MY170922A (en)	2011-12-22	2019-09-18	Novartis Ag	Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
CN104125955A (zh)	2011-12-23	2014-10-29	诺华股份有限公司	用于抑制bcl2与结合配偶体相互作用的化合物
US20130178520A1 (en)	2011-12-23	2013-07-11	Duke University	Methods of treatment using arylcyclopropylamine compounds
US9126979B2 (en)	2011-12-23	2015-09-08	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
CN104125953A (zh)	2011-12-23	2014-10-29	诺华股份有限公司	用于抑制bcl2与结合配偶体相互作用的化合物
CN104136429A (zh)	2011-12-23	2014-11-05	诺华股份有限公司	用于抑制bcl2与结合配偶体相互作用的化合物
AU2012355615A1 (en)	2011-12-23	2014-07-10	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
WO2013101600A1 (fr) *	2011-12-29	2013-07-04	Pharmacyclics, Inc.	Hydroxyamides d'acide cinnamique en tant qu'inhibiteurs d'histone désacétylase 8
JP2015508414A (ja)	2012-01-12	2015-03-19	イエールユニバーシティ	Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
JO3357B1 (ar)	2012-01-26	2019-03-13	Novartis Ag	مركبات إيميدازوبيروليدينون
AR092790A1 (es)	2012-02-01	2015-05-06	Euro Celtique Sa	Derivados bencimidazolicos del acido hidroxamico
CN110507654A (zh)	2012-04-03	2019-11-29	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
PT2861579T (pt)	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
JP6080947B2 (ja)	2012-05-15	2017-02-15	ノバルティスアーゲー	Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
US9278981B2 (en)	2012-05-15	2016-03-08	Novartis Ag	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9340537B2 (en)	2012-05-15	2016-05-17	Novatis Ag	Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
JP6171003B2 (ja)	2012-05-24	2017-07-26	ノバルティスアーゲー	ピロロピロリジノン化合物
WO2013188763A1 (fr)	2012-06-15	2013-12-19	The Brigham And Women's Hospital, Inc.	Compositions pour le traitement du cancer et leurs procédés de préparation
AR091773A1 (es)	2012-07-16	2015-02-25	Chdi Foundation Inc	Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso
WO2014025395A1 (fr)	2012-08-06	2014-02-13	Duke University	Composés et procédés pour le ciblage de hsp90
BR112015007083A2 (pt)	2012-10-02	2017-07-04	Epitherapeutics Aps	inibidores de histona demetilases
SMT202000168T1 (it)	2012-10-30	2020-05-08	Mei Pharma Inc	Terapie di combinazione per il trattamento dei tumori chemioresistenti
CA2888803A1 (fr)	2012-11-05	2014-05-08	Jooeun Bae	Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procedes d'utilisation de tels peptides et compositions
RU2015121367A (ru)	2012-11-08	2017-01-10	Новартис Аг	Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
US9556180B2 (en)	2013-01-22	2017-01-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014128612A1 (fr)	2013-02-20	2014-08-28	Novartis Ag	Dérivés de quinazolin-4-one
PE20151667A1 (es)	2013-02-27	2015-11-27	Epitherapeutics Aps	Inhibidores de histona desmetilasas
EP2968340A4 (fr)	2013-03-15	2016-08-10	Intellikine Llc	Combinaison d'inhibiteurs de kinase et ses utilisations
WO2014155268A2 (fr)	2013-03-25	2014-10-02	Novartis Ag	Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
EP2983674A4 (fr)	2013-04-08	2017-05-10	Dennis M. Brown	Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
CA2909160C (fr)	2013-04-09	2021-05-25	Lixte Biotechnology, Inc.	Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
HUE041881T2 (hu) *	2013-04-29	2019-06-28	Chong Kun Dang Pharmaceutical Corp	Új vegyületek mint szelektív hiszton dezacetiláz inhibitorok és az ezeket tartalmazó gyógyszerkészítmények
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
CA2928568A1 (fr)	2013-07-26	2015-01-29	Update Pharma Inc.	Procedes combinatoires permettant d'ameliorer l'avantage therapeutique du bisantrene
WO2015022664A1 (fr)	2013-08-14	2015-02-19	Novartis Ag	Composés et compositions utiles comme inhibiteurs de mek
WO2015022663A1 (fr)	2013-08-14	2015-02-19	Novartis Ag	Composés et compositions utiles comme inhibiteurs de mek
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
EP3046921A4 (fr)	2013-09-22	2017-02-22	Calitor Sciences, LLC	Composés d'aminopyrimidine substituée et procédés d'utilisation
EP3757130A1 (fr)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Méthodes de traitement de cancers hématologiques
CN103467359B (zh) *	2013-09-27	2015-04-22	山东大学	一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
WO2015084804A1 (fr)	2013-12-03	2015-06-11	Novartis Ag	Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
CN103664734B (zh) *	2013-12-10	2015-09-23	广州康缔安生物科技有限公司	杂环羟肟酸类化合物及其药用组合物和应用
EP3080125B1 (fr)	2013-12-12	2018-10-10	Chong Kun Dang Pharmaceutical Corp.	Nouveaux dérivés azaindole comme inhibiteurs sélectifs de l'histone désacétylase (hdac) et compositions pharmaceutiques les comprenant
KR101685639B1 (ko)	2014-01-03	2016-12-12	주식회사 종근당	신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
CA2935423C (fr)	2014-01-24	2023-11-07	Dana-Farber Cancer Institute, Inc.	Molecules d'anticorps anti-pd-1 et leurs utilisations
AU2015210750B2 (en)	2014-01-31	2020-08-20	Children's Medical Center Corporation	Antibody molecules to TIM-3 and uses thereof
EP4019518A1 (fr)	2014-02-28	2022-06-29	Nimbus Lakshmi, Inc.	Inhibiteurs de tyk2 et utilisations associées
WO2015138920A1 (fr)	2014-03-14	2015-09-17	Novartis Ag	Molécules d'anticorps anti-lag-3 et leurs utilisations
WO2015148714A1 (fr)	2014-03-25	2015-10-01	Duke University	Ligands de récepteurs de la protéine de choc thermique 70 (hsp-70)
JP6517319B2 (ja)	2014-03-28	2019-05-22	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されたヘテロアリール化合物および使用方法
EP3126345A1 (fr)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibiteurs d'histones déméthylases
RU2016140160A (ru)	2014-04-03	2018-05-07	Инвиктус Онколоджи Пвт. Лтд.	Супрамолекулярные комбинаторные лекарственные средства
CN119591582A (zh)	2014-04-14	2025-03-11	阿尔维纳斯运营股份有限公司	基于酰亚胺的蛋白水解调节剂和相关使用方法
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
GB201409485D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
GB201409488D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
GB201409471D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
WO2016011658A1 (fr)	2014-07-25	2016-01-28	Novartis Ag	Polythérapie
KR20170036037A (ko)	2014-07-31	2017-03-31	노파르티스 아게	조합 요법
US10071164B2 (en)	2014-08-11	2018-09-11	Yale University	Estrogen-related receptor alpha based protac compounds and associated methods of use
CN117164657A (zh)	2014-08-12	2023-12-05	莫纳什大学	定向淋巴的前药
EA201790154A1 (ru)	2014-08-27	2017-08-31	Джилид Сайэнс, Инк.	Соединения и способы для ингибирования гистоновых деметилаз
EP2995630A1 (fr)	2014-09-09	2016-03-16	Dublin Institute of Technology	Composés hybrides formés à partir de liquides ioniques et leurs utilisations dans des électrodes à sélectivité ionique
WO2016040882A1 (fr)	2014-09-13	2016-03-17	Novartis Ag	Polythérapie par les inhibiteurs de l'egfr
KR20170066546A (ko)	2014-10-03	2017-06-14	노파르티스 아게	조합 요법
KR102754019B1 (ko)	2014-10-29	2025-01-14	바이시클러드 리미티드	Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
ES2930585T3 (es)	2015-02-27	2022-12-19	Nimbus Lakshmi Inc	Inhibidores de TYK2 y usos de los mismos
JO3746B1 (ar)	2015-03-10	2021-01-31	Aduro Biotech Inc	تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
EP3932914A1 (fr)	2015-03-13	2022-01-05	Valo Health, Inc.	Composés alpha-cinnamidiques et compositions comme inhibiteurs de hdac8
JP7269731B2 (ja)	2015-03-18	2023-05-09	アルビナス・オペレーションズ・インコーポレイテッド	標的タンパク質の分解向上のための化合物および方法
CN108026057B (zh)	2015-05-22	2021-08-06	株式会社钟根堂	用作选择性组蛋白脱乙酰酶抑制剂的杂环烷基衍生化合物及含其的药物组合物
WO2017004133A1 (fr)	2015-06-29	2017-01-05	Nimbus Iris, Inc.	Inhibiteurs d'irak et utilisations de ceux-ci
WO2017004134A1 (fr)	2015-06-29	2017-01-05	Nimbus Iris, Inc.	Inhibiteurs d'irak et leurs utilisations
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016301196B2 (en)	2015-08-06	2022-09-08	Dana-Farber Cancer Institute, Inc.	Tunable endogenous protein degradation
WO2017032281A1 (fr) *	2015-08-21	2017-03-02	苏州晶云药物科技有限公司	Nouvelles formes cristallines de lactate de panobinostat
JP6802263B2 (ja)	2015-09-02	2020-12-16	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
EP3347340A4 (fr)	2015-09-08	2019-01-23	Monash University	Promédicaments ciblant la lymphe
EP3347097B1 (fr)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Dérivés d' aminopyrimidine substitués en tant que modulateurs des kinases jak, flt3 et aurora
AU2016342027B2 (en)	2015-10-23	2021-05-13	Navitor Pharmaceuticals, Inc.	Modulators of Sestrin-GATOR2 interaction and uses thereof
AU2016349781A1 (en)	2015-11-02	2018-05-10	Yale University	Proteolysis targeting chimera compounds and methods of preparing and using same
ITUB20155193A1 (it)	2015-11-03	2017-05-03	Italfarmaco Spa	Sospensioni orali di Givinostat fisicamente e chimicamente stabili
WO2017106332A1 (fr)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
ES2907489T3 (es)	2015-12-14	2022-04-25	X4 Pharmaceuticals Inc	Métodos para el tratamiento del cáncer
EP3389664A4 (fr)	2015-12-14	2020-01-08	Raze Therapeutics Inc.	Inhibiteurs de caféine de mthfd2 et leurs utilisations
HUE060517T2 (hu)	2015-12-22	2023-03-28	X4 Pharmaceuticals Inc	Immunhiányos betegség kezelésére szolgáló eljárások
CN105732467A (zh) *	2016-01-13	2016-07-06	深圳市康立生生物科技有限公司	一种panobinostat(帕比司他)的制备方法
EP3426244B1 (fr)	2016-03-09	2023-06-07	Raze Therapeutics, Inc.	Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
PT3426243T (pt)	2016-03-09	2021-08-19	Raze Therapeutics Inc	Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
ES3057783T3 (en)	2016-03-15	2026-03-04	Oryzon Genomics Sa	Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US11013698B2 (en)	2016-03-15	2021-05-25	Oryzon Genomics S.A.	Combinations of LSD1 inhibitors for the treatment of hematological malignancies
WO2017177230A1 (fr)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
US11261187B2 (en)	2016-04-22	2022-03-01	Duke University	Compounds and methods for targeting HSP90
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EP3455219A4 (fr)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
EP4483875A3 (fr)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Dégronimères spirocycliques pour la dégradation de protéines cibles
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
WO2017223229A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
CA3027500A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
EP3484858A4 (fr) *	2016-06-21	2020-02-26	The University of Melbourne	Activateurs de la latence du vih
WO2018015493A1 (fr)	2016-07-20	2018-01-25	Royal College Of Surgeons In Ireland	Complexes métalliques ayant des applications thérapeutiques
WO2018039203A1 (fr)	2016-08-23	2018-03-01	Oncopep, Inc.	Vaccins peptidiques et durvalumab pour le traitement du myélome multiple
US20190209669A1 (en)	2016-08-23	2019-07-11	Oncopep, Inc.	Peptide vaccines and durvalumab for treating breast cancer
WO2018054960A1 (fr)	2016-09-21	2018-03-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de prédiction et de traitement de la résistance à la chimiothérapie dans le lagc à npm-alk(+)
US10207998B2 (en)	2016-09-29	2019-02-19	Duke University	Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en)	2016-09-29	2021-02-23	Duke University	Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
AU2016426574B2 (en)	2016-10-11	2023-07-13	Euro-Celtique S.A.	Hodgkin lymphoma therapy
CN115448916B (zh)	2016-10-14	2026-04-28	武田药品工业株式会社	Tyk2抑制剂及其用途
JP7082120B2 (ja)	2016-10-21	2022-06-07	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
WO2018089499A1 (fr)	2016-11-08	2018-05-17	Navitor Pharmaceuticals, Inc.	Inhibiteurs de la phényl amino pipéridine mtorc et leurs utilisations
AU2017368050A1 (en)	2016-11-29	2019-06-20	Puretech Lyt, Inc.	Exosomes for delivery of therapeutic agents
US11091451B2 (en)	2016-12-05	2021-08-17	Raze Therapeutics, Inc.	SHMT inhibitors and uses thereof
WO2018107004A1 (fr)	2016-12-08	2018-06-14	Lixte Biotechnology, Inc.	Oxabicycloheptanes pour la modulation de la réponse immunitaire
US11730819B2 (en)	2016-12-23	2023-08-22	Bicycletx Limited	Peptide derivatives having novel linkage structures
WO2018127699A1 (fr)	2017-01-06	2018-07-12	Bicyclerd Limited	Composés permettant de traiter le cancer
EP3577109A4 (fr)	2017-01-31	2020-11-18	Arvinas Operations, Inc.	Ligands de céréblon et composés bifonctionnels les contenant
EP3580212A4 (fr)	2017-02-08	2021-03-17	Dana Farber Cancer Institute, Inc.	Régulation de récepteurs d'antigènes chimériques
TWI868528B (zh)	2017-03-08	2025-01-01	日商武田藥品工業股份有限公司	Ｔｙｋ２抑制劑之生產方法
EP3375778A1 (fr)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Dérivés d'aryl-pipéridine
EP3375784A1 (fr)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Dérivés d'aza-dihydro-acridone
WO2018191146A1 (fr)	2017-04-10	2018-10-18	Navitor Pharmaceuticals, Inc.	Inhibiteurs de rheb à base d'hétéroaryle et leurs utilisations
JOP20180036A1 (ar)	2017-04-18	2019-01-30	Vifor Int Ag	أملاح لمثبطات فروبورتين جديدة
US10857196B2 (en)	2017-04-27	2020-12-08	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107141244B (zh) *	2017-05-08	2019-11-19	潍坊医学院	吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
GB201709405D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating ovarian cancer
GB201709402D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating t-pll
GB201709406D0 (en)	2017-06-13	2017-07-26	Euro-Cletique S A	Compounds for treating TNBC
GB201709403D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating sarcoma
EP3641762B1 (fr)	2017-06-20	2026-02-18	C4 Therapeutics, Inc.	Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
CN111032678A (zh)	2017-06-26	2020-04-17	拜西克尔德有限公司	具有可检测部分的双环肽配体和其用途
WO2019023468A1 (fr)	2017-07-28	2019-01-31	Nimbus Lakshmi, Inc.	Inhibiteurs de tyk2 et leurs utilisations
ES2926195T3 (es)	2017-08-04	2022-10-24	Bicycletx Ltd	Ligandos peptídicos bicíclicos específicos de CD137
KR101977970B1 (ko)	2017-08-04	2019-05-14	중원대학교 산학협력단	신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
WO2019034866A1 (fr)	2017-08-14	2019-02-21	Bicyclerd Limited	Conjugués ligands peptidiques bicycliques et leurs utilisations
EP3668550A1 (fr)	2017-08-14	2020-06-24	Bicyclerd Limited	Conjugués peptide bicyclique-ligand ppr-a et leurs utilisations
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
WO2019046491A1 (fr)	2017-08-29	2019-03-07	Ariya Therapeutics, Inc.	Promédicaments lipidiques orientant vers le système lymphatique
JP7366031B2 (ja)	2017-09-22	2023-10-20	カイメラセラピューティクス，インコーポレイテッド	タンパク質分解剤およびそれらの使用
WO2019060693A1 (fr)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	Ligands crbn et utilisations de ces derniers
EP3461488A1 (fr)	2017-09-27	2019-04-03	Onxeo	Combinaison d'une molécule dbait et un inhibiteur de hdac pour le traitement du cancer
EP3461480A1 (fr)	2017-09-27	2019-04-03	Onxeo	Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
EP3700901A1 (fr)	2017-10-24	2020-09-02	Genentech, Inc.	Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation
WO2019083960A1 (fr)	2017-10-24	2019-05-02	Oncopep, Inc.	Vaccins peptidiques et inhibiteurs d'hdac pour le traitement du myélome multiple
US12059463B2 (en)	2017-10-24	2024-08-13	Oncopep, Inc.	Peptide vaccines and pembrolizumab for treating breast cancer
WO2019084030A1 (fr)	2017-10-24	2019-05-02	Genentech, Inc.	Composés de (4-hydroxypyrrolidin-2-yl)-hydroxamate et leurs procédés d'utilisation
WO2019099311A1 (fr)	2017-11-19	2019-05-23	Sunshine Lake Pharma Co., Ltd.	Composés hétéroaryle substitués et leurs méthodes d'utilisation
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
AU2017444054B2 (en)	2017-12-21	2021-10-07	Hefei Institutes Of Physical Science, Chinese Academy Of Sciences	Class of pyrimidine derivative kinase inhibitors
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
EP3737666A4 (fr)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Agents de dégradation de protéines et utilisations associées
US11512080B2 (en)	2018-01-12	2022-11-29	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
US10751339B2 (en)	2018-01-20	2020-08-25	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
EP4616913A3 (fr)	2018-01-29	2025-12-10	Merck Patent GmbH	Inhibiteurs de gcn2 et leurs utilisations
JP7377207B2 (ja)	2018-01-29	2023-11-09	メルクパテントゲーエムベーハー	Ｇｃｎ２阻害剤およびその使用
PL3752182T3 (pl)	2018-02-12	2024-11-25	Inimmune Corporation	Ligandy receptorów toll-podobnych
AU2019224659A1 (en)	2018-02-23	2020-10-15	Bicycletx Limited	Multimeric bicyclic peptide ligands
EP3759086A1 (fr)	2018-02-27	2021-01-06	Artax Biopharma Inc.	Dérivés de chromène en tant qu'inhibiteurs de l'interaction tcr-nck
WO2019183523A1 (fr)	2018-03-23	2019-09-26	Genentech, Inc.	Composés de dégradation hétéro-bifonctionnels et leur utilisation en tant que modulateurs de l'ubiquination ciblée (vhl)
EP3774772A1 (fr)	2018-04-13	2021-02-17	Arvinas Operations, Inc.	Ligands de céréblon et composés bifonctionnels les contenant
WO2019209757A1 (fr)	2018-04-24	2019-10-31	Vertex Pharmaceuticals Incorporated	Composés de ptéridinone et leurs utilisations
HUE067936T2 (hu)	2018-04-24	2024-11-28	Merck Patent Gmbh	Proliferáció-gátló vegyületek és alkalmazásuk
WO2019238886A1 (fr)	2018-06-13	2019-12-19	University Of Dundee	Molécules bifonctionnelles pour le ciblage de l'usp14
CN112533918A (zh)	2018-06-13	2021-03-19	安菲斯塔治疗有限责任公司	用于靶向Rpn11的双功能分子
CA3103205A1 (fr)	2018-06-13	2019-12-19	Amphista Therapeutics Ltd	Molecules bifonctionnelles pour cibler l'uchl5
IL314362A (en)	2018-06-15	2024-09-01	Janssen Pharmaceutica Nv	Rapamycin analogs and their uses
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
WO2020010177A1 (fr)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Ligands crbn tricycliques et leurs utilisations
EP3817822A4 (fr)	2018-07-06	2022-07-27	Kymera Therapeutics, Inc.	Agents de dégradation de protéines et leurs utilisations
CN108752255A (zh) *	2018-07-19	2018-11-06	重庆医科大学	一种帕比司他及其关键中间体的制备方法
EP3826988A4 (fr)	2018-07-24	2023-03-22	Hygia Pharmaceuticals, LLC	Composés, dérivés et analogues contre le cancer
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (fr)	2018-09-07	2024-01-24	PIC Therapeutics, Inc.	Inhibiteurs d'eif4e et leurs utilisations
CA3115088A1 (fr)	2018-10-15	2020-04-23	Nimbus Lakshmi, Inc.	Inhibiteurs de tyk2 et leurs utilisations
US10919937B2 (en)	2018-10-23	2021-02-16	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
CN109574936B (zh) *	2018-11-23	2022-02-22	沈阳药科大学	一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
CN113271938A (zh)	2018-11-30	2021-08-17	林伯士拉克许米公司	Tyk2抑制剂和其用途
JP7623943B2 (ja)	2018-11-30	2025-01-29	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
GB201820295D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for psma
GB201820288D0 (en)	2018-12-13	2019-01-30	Bicycle Tx Ltd	Bicycle peptide ligaands specific for MT1-MMP
WO2020128913A1 (fr)	2018-12-18	2020-06-25	Mundipharma International Corporation Limited	Composés pour traiter un myélome multiple
EP3670659A1 (fr)	2018-12-20	2020-06-24	Abivax	Biomarqueurs et leurs utilisations dans le traitement d'infections virales, d'inflammations ou du cancer
CN120698983A (zh)	2018-12-20	2025-09-26	C4医药公司	靶向蛋白降解
CN113474045A (zh)	2018-12-21	2021-10-01	拜斯科技术开发有限公司	Pd-l1特异性的双环肽配体
US12551567B2 (en)	2018-12-21	2026-02-17	Bicyclerd Limited	Bicyclic peptide ligands specific for PD-L1
AU2020212001A1 (en)	2019-01-23	2021-07-22	Takeda Pharmaceutical Company Limited	TYK2 inhibitors and uses thereof
WO2020165600A1 (fr)	2019-02-14	2020-08-20	Bicycletx Limited	Conjugués peptide-ligand bicyclique et leurs utilisations
JP2022528887A (ja)	2019-04-02	2022-06-16	バイスクルテクス・リミテッド	バイシクルトキシンコンジュゲートおよびその使用
US11485750B1 (en)	2019-04-05	2022-11-01	Kymera Therapeutics, Inc.	STAT degraders and uses thereof
WO2020243423A1 (fr)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
WO2020251972A1 (fr)	2019-06-10	2020-12-17	Kymera Therapeutics, Inc.	Agents de dégradation de smarca et leurs utilisations
WO2020251971A1 (fr)	2019-06-10	2020-12-17	Kymera Therapeutics, Inc.	Agents de dégradation de smarca et leurs utilisations
BR112021026517A2 (pt)	2019-06-28	2022-05-10	Kymera Therapeutics Inc	Degradadores de irak e usos dos mesmos
WO2021011868A1 (fr)	2019-07-17	2021-01-21	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
TWI860386B (zh)	2019-07-30	2024-11-01	英商拜西可泰克斯有限公司	異質雙環肽複合物
GB201913121D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
CN115038688A (zh)	2019-09-11	2022-09-09	文森雷生物科学股份有限公司	Usp30抑制剂及其用途
GB201913124D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
GB201913123D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
GB201913122D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
PH12022550605A1 (en)	2019-09-13	2023-09-25	Nimbus Saturn Inc	Hpk1 antagonists and uses thereof
US20220340933A1 (en)	2019-09-25	2022-10-27	University College Dublin	Nanoparticle compositions for gene therapy
EP3798250A1 (fr)	2019-09-25	2021-03-31	University College Dublin	Polymères cationiques hyperramifiés utiles en tant que vecteurs d'administration d'acide nucléique pour la transfection
WO2021092174A1 (fr) *	2019-11-06	2021-05-14	Dana-Farber Cancer Institute, Inc.	Agents de dégradation sélectif de l'histone déacétylase (hdac) et leurs procédés d'utilisation
BR112022010754A2 (pt)	2019-12-05	2022-08-23	Anakuria Therapeutics Inc	Análogos de rapamicina e usos dos mesmos
EP4072591A4 (fr)	2019-12-10	2024-06-05	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
JP2023509366A (ja)	2019-12-17	2023-03-08	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
WO2021127283A2 (fr)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
EP4077309A1 (fr)	2019-12-19	2022-10-26	Arvinas Operations, Inc.	Composés et méthodes pour la dégradation ciblée du récepteur des androgènes
US12569485B2 (en)	2019-12-23	2026-03-10	Kymera Therapeutics, Inc.	SMARCA inhibitors and uses thereof
CN115297931A (zh)	2019-12-23	2022-11-04	凯麦拉医疗公司	Smarca降解剂和其用途
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
AU2021217172A1 (en)	2020-02-05	2022-09-22	Monash University	Lipid prodrugs of neurosteroids
IT202000004075A1 (it)	2020-02-27	2021-08-27	Flamma Spa	Processo per la preparazione di panobinostat
MX2022010944A (es)	2020-03-03	2022-11-09	Pic Therapeutics Inc	Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
JP2023517956A (ja)	2020-03-10	2023-04-27	エックス４ファーマシューティカルズ，インコーポレイテッド	好中球減少症を処置する方法
WO2021185844A1 (fr)	2020-03-16	2021-09-23	Pvac Medical Technologies Ltd	Utilisation d'une substance et composition pharmaceutique correspondante et traitements médicaux ou utilisations correspondants
WO2021233534A1 (fr)	2020-05-20	2021-11-25	Pvac Medical Technologies Ltd	Utilisation d'une substance et composition pharmaceutique associée, et traitements médicaux ou utilisations associées
IL296451B2 (en)	2020-03-19	2026-05-01	Kymera Therapeutics Inc	MDM2 joints and their uses
EP4136228A4 (fr)	2020-04-15	2024-09-11	California Institute of Technology	Régulation thermique de l'immunothérapie par lymphocytes t par actionnement moléculaire et physique
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
WO2021247897A1 (fr)	2020-06-03	2021-12-09	Kymera Therapeutics, Inc.	Agents de dégradation d'irak deutérés et leurs utilisations
CA3189761A1 (fr)	2020-08-03	2022-02-10	Gemma Mudd	Lieurs a base de peptides
WO2022029220A1 (fr)	2020-08-05	2022-02-10	Ellipses Pharma Ltd	Traitement du cancer à l'aide d'un conjugué polymère contenant de la cyclodextrine-inhibiteur de la topoisomérase et d'un inhibiteur de parp
KR20230074721A (ko)	2020-08-17	2023-05-31	바이사이클티엑스 리미티드	Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
US11999964B2 (en)	2020-08-28	2024-06-04	California Institute Of Technology	Synthetic mammalian signaling circuits for robust cell population control
JP2023546996A (ja)	2020-10-23	2023-11-08	ニンバスクロソー，インコーポレイテッド	Ｃｔｐｓ１阻害剤およびその使用
WO2022120353A1 (fr)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
IL303376A (en)	2020-12-02	2023-08-01	Ikena Oncology Inc	Tead inhibitors and uses thereof
EP4259144A4 (fr)	2020-12-09	2025-08-20	Kymera Therapeutics Inc	Agents de dégradation de smarca et leurs utilisations
PE20240545A1 (es)	2020-12-18	2024-03-19	Amphista Therapeutics Ltd	Moleculas bifuncionales novedosas para la degradacion de proteinas dirigidas
GB202020359D0 (en)	2020-12-22	2021-02-03	Midatech Pharma Wales Ltd	Pharmaceutical compositions and use thereof in combination therapy for brain cancer
WO2022147465A1 (fr)	2020-12-30	2022-07-07	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
KR20230153387A (ko)	2021-02-02	2023-11-06	리미널 바이오사이언시스 리미티드	Gpr84 길항제 및 이의 용도
JP2024506858A (ja)	2021-02-02	2024-02-15	リミナル・バイオサイエンシーズ・リミテッド	Ｇｐｒ８４アンタゴニストおよびその使用
TW202245788A (zh)	2021-02-15	2022-12-01	美商凱麥拉醫療公司	Irak4降解劑及其用途
EP4319756A4 (fr)	2021-04-09	2025-02-26	Nimbus Clio, Inc.	Modulateurs de cbl-b et leurs utilisations
WO2022221866A1 (fr)	2021-04-16	2022-10-20	Ikena Oncology, Inc.	Inhibiteurs de mek et leurs utilisations
AU2022271290A1 (en)	2021-05-07	2023-11-23	Kymera Therapeutics, Inc.	Cdk2 degraders and uses thereof
JP2024532276A (ja)	2021-08-25	2024-09-05	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
TW202315621A (zh)	2021-08-25	2023-04-16	美商皮克醫療公司	Ｅｉｆ４ｅ抑制劑及其用途
EP4405680A1 (fr)	2021-09-20	2024-07-31	Institut National de la Santé et de la Recherche Médicale (INSERM)	Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
GB2611043A (en)	2021-09-22	2023-03-29	Univ Dublin City	A cis-platinum(II)-oligomer hybrid
EP4422635A4 (fr)	2021-10-29	2025-11-26	Kymera Therapeutics Inc	Agents de dégradation d'irak4 et leur synthèse
EP4433031A1 (fr)	2021-11-19	2024-09-25	Branca Bunus Limited	Composition comprenant un agent thérapeutiquement actif enrobé dans un véhicule d'administration de médicament
WO2023114984A1 (fr)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
IL314437A (en)	2022-01-31	2024-09-01	Kymera Therapeutics Inc	IRAK joints and their uses
WO2023173053A1 (fr)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Inhibiteurs de mek et leurs utilisations
WO2023173057A1 (fr)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Inhibiteurs de mek et leurs utilisations
EP4504165A1 (fr)	2022-04-05	2025-02-12	Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale	Combinaison d'inhibiteurs de hdac et de statines pour une utilisation dans le traitement du cancer du pancréas
GB2617409B (en)	2022-04-27	2024-06-26	Cancertain Ltd	Method for predicting responsiveness to therapy
WO2023211889A1 (fr)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Composés polymorphes et leurs utilisations
KR20250040894A (ko)	2022-05-25	2025-03-25	이케나 온콜로지, 인코포레이티드	Mek 억제제 및 이의 용도
JP2025525347A (ja)	2022-06-16	2025-08-05	アンフィスタセラピューティクスリミテッド	標的タンパク質分解のための新規の二官能性分子
JP2025527248A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
JP2025527247A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
AU2023317584A1 (en)	2022-08-02	2025-02-13	Luca Science Inc.	Methods of improving cellular therapy with organelle complexes
JP2025527250A (ja)	2022-08-02	2025-08-20	リミナル・バイオサイエンシーズ・リミテッド	ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
EP4577210A1 (fr)	2022-08-26	2025-07-02	Biodexa Ltd.	Polythérapie pour le cancer du cerveau
TW202430148A (zh)	2022-11-22	2024-08-01	美商皮克醫療公司	ｅＩＦ４Ｅ抑制劑及其用途
WO2024184266A1 (fr)	2023-03-03	2024-09-12	Ionctura Sa	Combinaison de roginolisib et d'un inhibiteur de hdac dans le traitement d'une malignité hématologique
EP4615455A2 (fr)	2023-06-23	2025-09-17	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
WO2025026925A1 (fr)	2023-07-28	2025-02-06	Ospedale San Raffaele S.R.L.	Inhibiteurs de gtf2i et leurs utilisations
CN119490449B (zh) *	2023-08-16	2025-11-21	沈阳药科大学	含n-苄基-2-(5-苯基吡啶-2-基)乙酰胺的异羟肟酸类化合物及制备方法和应用
AU2024344754A1 (en)	2023-09-21	2026-04-02	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2025078542A1 (fr)	2023-10-11	2025-04-17	Technological University Dublin	Complexes coumarine-métal et leurs utilisations
CN118027033A (zh) *	2024-01-26	2024-05-14	四川大学	一种hdac6抑制剂及其制备方法和在抗炎和溃疡性结肠炎中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995031977A1 (fr) *	1994-05-19	1995-11-30	Sloan-Kettering Institute For Cancer Research	Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0570594B1 (fr)	1991-12-10	1997-07-30	Shionogi & Co., Ltd.	Derive d'acide hydroxamique a base de sulfonamide aromatique
GB9215665D0 (en) *	1992-07-23	1992-09-09	British Bio Technology	Compounds
US5569668A (en) *	1995-03-29	1996-10-29	Webster; John M.	Indole derivatives with antibacterial and antimycotic properties
US5722242A (en) *	1995-12-15	1998-03-03	Borealis Technical Limited	Method and apparatus for improved vacuum diode heat pump
US6777217B1 (en)	1996-03-26	2004-08-17	President And Fellows Of Harvard College	Histone deacetylases, and uses related thereto
JPH10182583A (ja)	1996-12-25	1998-07-07	Mitsui Chem Inc	新規ヒドロキサム酸誘導体
AUPO721997A0 (en) *	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
US6127392A (en)	1997-08-05	2000-10-03	American Home Products Corporation	Anthranilic acid analogs
BR9811845A (pt)	1997-08-05	2000-08-08	American Home Prod	Análogos do ácido antranìlico
ATE275956T1 (de)	1998-10-19	2004-10-15	Methylgene Inc	Veränderung der dns methyltransferase durch kombinationstherapie
US6110922A (en)	1998-12-29	2000-08-29	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
UA74781C2 (en)	1999-04-02	2006-02-15	Abbott Lab	Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion
MXPA02002505A (es)	1999-09-08	2004-09-10	Sloan Kettering Inst Cancer	Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
GB9922173D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
CA2391952C (fr) *	1999-11-23	2012-01-31	Methylgene Inc.	Inhibiteurs de l'histone deacetylase
WO2001042437A2 (fr)	1999-12-08	2001-06-14	Axys Pharmaceuticals, Inc.	Proteines histone deacetylase-8, acides nucleiques et technique d'utilisation
TW427572U (en) *	1999-12-17	2001-03-21	Hon Hai Prec Ind Co Ltd	Electrical connector
EP1438404A2 (fr)	2000-03-24	2004-07-21	Methylgene, Inc.	Inhibition d'isoformes specifiques d'histone deacetylase
AU2001248701A1 (en)	2000-03-24	2001-10-03	Methylgene, Inc.	Inhibitors of histone deacetylase
WO2002018326A1 (fr)	2000-08-31	2002-03-07	Wakunaga Pharmaceutical Co., Ltd.	Nouveaux derives d'acide propenohydroxamique
PE20020354A1 (es) *	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
RU2003112691A (ru)	2000-10-05	2004-09-20	Фудзисава Фармасьютикал Ко.,Лтд. (Jp)	Бензамидные соединения в качестве ингибиторов секреции аро в
SE0101386D0 (sv)	2001-04-20	2001-04-20	Astrazeneca Ab	New compounds
US6905669B2 (en)	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ2004220A3 (cs)	2001-08-11	2004-06-16	Bristol-Myers Squibb Pharma Company	Název neuveden
US6706686B2 (en) *	2001-09-27	2004-03-16	The Regents Of The University Of Colorado	Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
DE10152764A1 (de) *	2001-10-29	2003-05-08	Linde Ag	Ventil für kryogene Medien

2001
- 2001-08-28 PE PE2001000866A patent/PE20020354A1/es not_active Application Discontinuation
- 2001-08-30 AU AU2001282129A patent/AU2001282129B2/en not_active Ceased
- 2001-08-30 IL IL15457401A patent/IL154574A0/xx unknown
- 2001-08-30 PL PL361408A patent/PL221738B1/pl unknown
- 2001-08-30 AT AT01960717T patent/ATE376999T1/de active
- 2001-08-30 JP JP2002526830A patent/JP4012819B2/ja not_active Expired - Lifetime
- 2001-08-30 EP EP01960717A patent/EP1318980B1/fr not_active Expired - Lifetime
- 2001-08-30 KR KR1020037002446A patent/KR100585484B1/ko not_active Expired - Fee Related
- 2001-08-30 SI SI200130803T patent/SI1318980T1/sl unknown
- 2001-08-30 MY MYPI20014079A patent/MY136892A/en unknown
- 2001-08-30 CN CNB018150675A patent/CN1300110C/zh not_active Expired - Lifetime
- 2001-08-30 AU AU8212901A patent/AU8212901A/xx active Pending
- 2001-08-30 CA CA2420899A patent/CA2420899C/fr not_active Expired - Lifetime
- 2001-08-30 RU RU2003108857A patent/RU2302408C3/ru not_active IP Right Cessation
- 2001-08-30 BR BRPI0113669A patent/BRPI0113669B8/pt not_active IP Right Cessation
- 2001-08-30 SK SK242-2003A patent/SK287609B6/sk not_active IP Right Cessation
- 2001-08-30 WO PCT/EP2001/010037 patent/WO2002022577A2/fr not_active Ceased
- 2001-08-30 CZ CZ20030573A patent/CZ302707B6/cs not_active IP Right Cessation
- 2001-08-30 ES ES01960717T patent/ES2292610T3/es not_active Expired - Lifetime
- 2001-08-30 NZ NZ524365A patent/NZ524365A/en not_active IP Right Cessation
- 2001-08-30 DK DK01960717T patent/DK1318980T3/da active
- 2001-08-30 HU HU0300880A patent/HU229796B1/hu active Protection Beyond IP Right Term
- 2001-08-30 PT PT01960717T patent/PT1318980E/pt unknown
- 2001-08-30 MX MXPA03001832A patent/MXPA03001832A/es active IP Right Grant
- 2001-08-30 AR ARP010104140A patent/AR035057A1/es active IP Right Grant
- 2001-08-30 DE DE60131179T patent/DE60131179T2/de not_active Expired - Lifetime
- 2001-08-30 EP EP07115019A patent/EP1870399A1/fr not_active Withdrawn
- 2001-08-31 US US09/944,275 patent/US6552065B2/en not_active Expired - Lifetime
- 2001-08-31 TW TW090121617A patent/TWI286544B/zh not_active IP Right Cessation
2002
- 2002-11-19 US US10/299,518 patent/US6833384B2/en active Active
2003
- 2003-02-20 IL IL154574A patent/IL154574A/en active IP Right Grant
- 2003-02-21 ZA ZA200301423A patent/ZA200301423B/en unknown
- 2003-02-25 EC EC2003004492A patent/ECSP034492A/es unknown
- 2003-02-25 NO NO20030867A patent/NO324942B1/no not_active IP Right Cessation
2004
- 2004-11-09 US US10/984,501 patent/US7067551B2/en not_active Expired - Lifetime
2006
- 2006-04-20 US US11/408,129 patent/US20060189674A1/en not_active Abandoned
2007
- 2007-12-19 CY CY20071101619T patent/CY1107839T1/el unknown
2008
- 2008-03-11 US US12/045,885 patent/US20080176849A1/en not_active Abandoned
2015
- 2015-11-30 NL NL300778C patent/NL300778I2/nl unknown
- 2015-12-01 LU LU92890C patent/LU92890I2/fr unknown
- 2015-12-03 BE BE2015C062C patent/BE2015C062I2/fr unknown
- 2015-12-08 FR FR15C0086C patent/FR15C0086I2/fr active Active
- 2015-12-10 NO NO2015026C patent/NO2015026I2/no not_active IP Right Cessation
- 2015-12-14 CY CY2015053C patent/CY2015053I1/el unknown
- 2015-12-16 HU HUS1500068C patent/HUS1500068I1/hu unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995031977A1 (fr) *	1994-05-19	1995-11-30	Sloan-Kettering Institute For Cancer Research	Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation

Also Published As

Publication number	Publication date
NL300778I2 (fr)	2016-06-30
MY136892A (en)	2008-11-28
AR035057A1 (es)	2004-04-14
CY2015053I2 (el)	2016-06-22
ECSP034492A (es)	2003-04-25
FR15C0086I2 (fr)	2016-06-03
NO2015026I1 (no)	2015-12-10
US20040024067A1 (en)	2004-02-05
EP1318980B1 (fr)	2007-10-31
WO2002022577A3 (fr)	2002-09-06
NO2015026I2 (no)	2015-12-28
WO2002022577A2 (fr)	2002-03-21
MXPA03001832A (es)	2003-06-04
CA2420899A1 (fr)	2002-03-21
EP1870399A1 (fr)	2007-12-26
US20030018062A1 (en)	2003-01-23
PL361408A1 (en)	2004-10-04
NO20030867D0 (no)	2003-02-25
PT1318980E (pt)	2008-01-17
FR15C0086I1 (fr)	2016-01-15
CZ2003573A3 (cs)	2003-06-18
DK1318980T3 (da)	2008-02-11
IL154574A0 (en)	2003-09-17
CY2015053I1 (el)	2016-06-22
IL154574A (en)	2010-02-17
JP2004509105A (ja)	2004-03-25
ES2292610T3 (es)	2008-03-16
RU2302408C3 (ru)	2018-06-01
HUP0300880A2 (hu)	2003-08-28
TWI286544B (en)	2007-09-11
LU92890I2 (fr)	2016-02-01
KR20030031986A (ko)	2003-04-23
US20080176849A1 (en)	2008-07-24
AU2001282129B2 (en)	2005-08-25
RU2302408C2 (ru)	2007-07-10
US20050085507A1 (en)	2005-04-21
CY1107839T1 (el)	2013-06-19
CZ302707B6 (cs)	2011-09-14
SK2422003A3 (en)	2003-09-11
BRPI0113669B1 (pt)	2017-06-06
PE20020354A1 (es)	2002-06-12
CN1450991A (zh)	2003-10-22
HUP0300880A3 (en)	2010-03-29
ATE376999T1 (de)	2007-11-15
CA2420899C (fr)	2011-03-08
CN1300110C (zh)	2007-02-14
AU8212901A (en)	2002-03-26
NZ524365A (en)	2004-11-26
JP4012819B2 (ja)	2007-11-21
HU229796B1 (en)	2014-07-28
US20060189674A1 (en)	2006-08-24
DE60131179T2 (de)	2008-03-06
DE60131179D1 (en)	2007-12-13
SK287609B6 (sk)	2011-04-05
PL221738B1 (pl)	2016-05-31
US6552065B2 (en)	2003-04-22
ZA200301423B (en)	2004-04-21
KR100585484B1 (ko)	2006-06-07
HUS1500068I1 (hu)	2018-05-02
US6833384B2 (en)	2004-12-21
BR0113669A (pt)	2003-06-03
US7067551B2 (en)	2006-06-27
HK1057746A1 (en)	2004-04-16
BE2015C062I2 (fr)	2021-01-28
SI1318980T1 (sl)	2008-08-31
BRPI0113669B8 (pt)	2021-05-25
NO20030867L (no)	2003-02-25
EP1318980A2 (fr)	2003-06-18

Legal Events

Date	Code	Title	Description
2016-12-05	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: PANOBINOSTAT ELLER ET FARMASOYTISK AKSEPTABELT SALT DERAV; REGISTRATION NO/DATE: EU/1/15/1023 20150901 Spc suppl protection certif: 2015026 Filing date: 20151210
2020-04-06	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: SECURA BIO, US
2020-04-06	SPCS	Change of name or address of the owner of a supplementary protection certificate	Owner name: SECURA BIO, CH Spc suppl protection certif: 2015026
2021-09-13	MK1K	Patent expired

Publication	Publication Date	Title
EP1318980B1 (fr)	2007-10-31	Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
AU2001282129A1 (en)	2002-06-13	Hydroxamate derivatives useful as deacetylase inhibitors
EP2412706B1 (fr)	2014-10-29	Nouveau dérivé hydroxamate, procédé de production associé, et composition pharmaceutique comprenant le dérivé
EP3294715B1 (fr)	2020-05-06	Dérivés de benzimidazole utiles en tant qu'inhibiteurs de l'activité de l'histone désacétylase de mammifère
CN110845425A (zh)	2020-02-28	一种酞嗪衍生物及其制备方法和应用
CN114524799B (zh)	2023-05-26	一种hdac抑制剂及其制备方法和用途
CN105669556B (zh)	2017-12-15	一种具有抗肿瘤活性的3‑取代吡唑‑5‑酰胺类化合物及其应用
CN102149678A (zh)	2011-08-10	用于治疗癌症的新型邻氨基酰苯胺类
CN101012201B (zh)	2010-07-28	川芎嗪衍生物、其制备方法及其医药用途
CN105801464A (zh)	2016-07-27	吡咯酰胺类化合物及其制备方法与用途
WO2016107541A1 (fr)	2016-07-07	Composé de pyrrole-amide, son procédé de préparation et son utilisation
KR100464526B1 (ko)	2005-01-03	나트륨-수소 교환체 타입 1 억제제 결정
CN106496132B (zh)	2019-03-08	N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
HK1057746B (en)	2008-04-25	Hydroxamate derivatives useful as deacetylase inhibitors
CN111548286B (zh)	2022-09-06	一种具有hdac3抑制活性的psa衍生物及其应用
WO2016107542A1 (fr)	2016-07-07	Composé pyrrole amide, son procédé de préparation et son utilisation